Triple-negative breast cancer (~ 15% of all breast cancers) lacks expression of ER, PR, and HER2, making targeted therapies ineffective and resulting in worse survival rates compared to other subtypes [3–5]. The gene discussed is ERBB2; the disease is breast cancer.